1 min read
Add as a preferred source on GoogleMaze Therapeutics Posts $0.79 Q3 GAAP Loss Per Share as R&D Costs Rise
Net loss reached $48 million. Cash, cash equivalents and marketable securities totaled $477 million on Sept. 30, 2026.
Maze Therapeutics, Inc. posted a $0.79 GAAP loss per share for the third quarter of 2026 as its net loss expanded and research costs rose from a year earlier.
Maze's net loss was $48 million, compared with $30.1 million in Q3 2025. Research and development expenses climbed 59.7% year over year to $40.2 million from $25.2 million.
The company had $477 million in cash, cash equivalents and marketable securities on Sept. 30, 2026. That balance was $360 million on Dec. 31, 2025.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.